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Abstract
Introduction Ventricular access devices (VAD) and
ventriculosubgaleal shunts (VSGS) are currently both used as
temporising devices to affect CSF drainage in neonatal
posthaemorrhagic hydrocephalus (PHH), without clear evidence
of superiority of either procedure. In this systematic review and
meta-analysis, we compared the VSGS and VAD regarding
complication rates, ventriculoperitoneal shunt conversion and
infection rates, and mortality and long-term disability.
Methods The review was registered with the PROSPERO in-
ternational prospective register of systematic reviews (regis-
tration number CRD42015019750) and was conducted in ac-
cordance with PRISMA guidelines.
Results and conclusions The literature search of five databases
identified 338 publications, of which 5met the inclusion criteria.
All were retrospective cohort studies (evidence class 3b and 4).
A significantly lower proportion of patients with a VSGS re-
quired CSF tapping compared to patients with a VAD (log OR
−4.43, 95%CI −6.14 to −2.72). No other significant differences
between the VAD and VSGS were identified in their rates of
infection (log OR 0.03, 95 %CI −0.77 to 0.84), obstruction (log
OR 1.25, 95 % CI −0.21 to 2.71), ventriculoperitoneal shunt
dependence (log OR −0.06, 95 % CI −0.93 to 0.82), subsequent
shunt infection (log OR 0.23, 95 % CI −0.61 to 1.06), mortality
(log OR 0.37, 95 % CI −0.95 to 1.70) or long-term disability
(p = 0.9). In all studies, there was a lack of standardised criteria,
variations between surgeons in heterogeneous cohorts of limited
sample size and a lack of neurodevelopmental follow-up. This
affirms the importance of an ongoing multicentre, prospective
pilot study comparing these two temporising procedures to en-
able a more robust comparison.
Keywords Intraventricular haemorrhage . Posthaemorrhagic
hydrocephalus . Ventricular access device .
Ventriculosubgaleal shunt
Introduction
Preterm infants, particularly those classed as Bextremely
low birth weight^ (<1000 kg), are at risk of bleeding from
the germinal matrix of the developing brain, resulting in
intraventricular haemorrhage (IVH). Depending on the
grade of IVH, 25–80 % of affected infants develop radio-
logical posthaemorrhagic ventricular dilatation (PHVD)
and clinical evidence of posthaemorrhagic hydrocephalus
(PHH) [1]. Preterm IVH is an important clinical problem in
these children: PHH has been associated with significantly
impaired long-term neurodevelopment [2]. PHH has been
shown to result in a three-fold increase in cognitive and
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psychomotor delay, with nearly a third of patients suffering
from epilepsy [3]. Furthermore, IVH is an independent risk
factor for cerebral palsy [4, 5].
The definitive treatment for PHH is CSF diversion
achieved by insertion of a ventriculoperitoneal shunt
(VPS). Insertion of VPS is discouraged in infants weighing
less than 2 kg due to immunological immaturity, technical
factors and the risk of abdominal sepsis [6, 7]. They may
also often have significant co-morbidities, including sep-
sis, respiratory impairment and abdominal complications
such as necrotising enterocolitis [4]. In addition, a propor-
tion of infants may not require permanent CSF drainage
after clearance of the intraventricular blood [8, 9]. There-
fore, in the interim, progressive symptomatic ventricular
dilatation is often treated with temporary CSF diversion,
with measures including lumbar punctures, ventricular tap-
ping, external ventricular drains (EVDs) and the so-called
temporising devices (TDs—see below). In previous sys-
tematic analyses, early repeated CSF tapping using lumbar
punctures and ventricular tapping could not be recom-
mended; lumbar punctures did not change outcomes in
comparison to observation [10, 11]. The two most well-
established TDs are a ventricular access device (VAD)
and a ventriculosubgaleal shunt (VSGS). A VAD involves
insertion of a subcutaneous reservoir connected to a ven-
tricular catheter for percutaneous CSF tapping [12]; typi-
cally, these are aspirated percutaneously at regular inter-
vals (e.g. every 12–48 h) in order to maintain head circum-
ference [13]. A VSGS is a CSF shunt with the ventricular
catheter draining directly into a subgaleal scalp pocket,
created during the surgical procedure [4, 14]. There is ev-
idence that VADs reduce morbidity and mortality com-
pared with EVDs [11].
There are theoretical advantages in using a VSGS in-
stead of a VAD; the VSGS permits resorption through a
subgaleal scalp pocket, reducing the need for intermittent
tapping required with a VAD [12, 14]. The VSGS also
establishes a permanent decompression without causing
electrolyte and nutritional losses [15]. However, potential
complications of the use of a VSGS include scarring of the
subgaleal pocket [14, 16], and/or CSF leakage [16–18],
and some series report significant infection and failure
rates [17, 19].
Currently, there is no strong evidence favouring the use of
one particular TD over another, and the choice of which to use
in a particular case is often down to the experience and pref-
erence of the treating neurosurgeon. Differences in outcomes
between VADs and VSGSs as for the management of PHH
remain poorly understood [11]. Therefore, this systematic re-
view sought to compare VAD and VSGS in key outcomes
such as complication rate (including infection and failure),
permanent VPS requirement rate, long-term disability and
mortality in neonates with PHH.
Methods
This systematic review was conducted according to the
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines and has been regis-
tered with the PROSPERO international prospective register
o f s y s t em a t i c r e v i ew s ( r e g i s t r a t i o n n umb e r
CRD42015019750). A systematic search of keywords in
Table 1 was performed independently by two authors (DMF
and DA) of MEDLINE Complete via EBSCOhost, EMBASE
1974 to 2015 via Ovid, the Cochrane Central Register of Con-
trolled Trials (CENTRAL) via the Cochrane Library and
ClinicalTrials.gov databases on the 22nd April 2015. A
record of our MEDLINE Complete search is provided in the
Electronic Supplementary Material (Table S1).
Initially, titles and abstracts were screened for relevant pa-
pers. The full texts were then attained and reviewed. Both
processes were undertaken by two authors independently
(DMF and DA). Decisions were blinded and, where disagree-
ments occurred, both authors discussed the disparities and
resolved them throughout the selection process. Data extrac-
tion was also performed by two authors (DMF and DA) to
ensure reliability.Where inconsistent reporting formats of data
were published, authors were contacted directly to enable col-
lection of comparable data using a standardised data collection
template (Electronic Supplementary Material Table S2). The
inclusion criteria were as follows:
1. Study design: Peer-reviewed published original research.
Abstracts, commentaries, reviews and research without
peer review were excluded.
2. Population: At least 10 patients with posthaemorrhagic
hydrocephalus of prematurity (PHH).
3. Intervention: Use of ventricular access device (VAD) and
ventriculosubgaleal shunt (VSGS) in a comparative study.
4. Outcome: Results including at least one of the following:
Table 1 Search terms used in the literature review
Population Problem Intervention
Infant Hemorrhage Ommaya Reservoir*
Infant, Newborn Hydrocephalus VAD
Infant* Hemorrhag* Ventricular Access Device*
Neonat* Haemorrhag* Ventricular Reservoir*
Intraventricular Subcutaneous Reservoir*
Intra Ventricular VSGS
Posthemorrhagic Subgaleal Shunt*
Posthaemorrhagic Ventriculosubgaleal Shunt*
Post Hemorrhagic
Post Haemorrhagic
Medical Subject Headings (MeSH) are shaded in grey. Booleans BOR^
and BAND^were utilised to combine row and column terms, respectively
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a. Rate of TD infection and obstruction
b. VPS conversion rate
c. Subsequent VPS infection
d. Mortality.
Evidence classification for accepted studies was performed
based on the Oxford Centre for Evidence-based Medicine—
Levels of Evidence [20]. All studies were appraised for their
quality of reporting using the STROBE statement alongside
separate evaluation of methods and validity of conclusions
[21].Where reported, data on eachmajor outcomewas convert-
ed to a log odds ratio (OR) with 95 % confidence interval (CI)
and combined across studies in a meta-analysis. Reporting of
meta-analysis was undertaken in accordance with the proposed
checklist published by the Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) group [22]. Pooling of
OR estimates was performed using an inverse variance weight
random-effects DerSimonian-Laird meta-analysis, with
Cochran’s Q test for heterogeneity [23]. If the Q test value
was less than (k-1), where k = number of studies, fixed-effects
method was also reviewed for consistency of results as a sen-
sitivity analysis. All statistical analysis was performed using the
metafor package in R, version 3.0.2 [24, 25].
A flow diagram for the results of the systematic search
process is provided in the Electronic Supplementary Material
(Figure S1). Forward and backward searching of accepted
papers was also performed to identify additional studies not
captured in the systematic search results. The search was re-
peated on 19th August 2015. No additional studies were
identified.
Results
Five original research studies were identified, all retrospective
cohort studies (Table 2). Three studies [8, 26, 27] were clas-
sified as class 3b due to tested homogeneity of birth weight
and gestational age between cohorts. Wang et al. tested the
cohorts and found them to be significantly heterogeneous,
whereas Wellons et al. conducted no testing for homogeneity
of cohorts [28, 29]. Both studies were thus assigned as evi-
dence class 4. Meta-analysis of the published data where
pooling was possible is presented in Fig.1. Across all outcome
measures, Cochran’s Q test for heterogeneity was non-
significant (p > 0.05). Fixed effect sensitivity analysis provid-
ed consistent results where performed.
Temporising device CSF taps, infection and obstruction
Two studies evaluated CSF tapping. Wang et al. identified a
significantly higher number of CSF taps in patients with
VADs than VSGSs (VAD 10 ± 8.7 taps vs. VSGS 1.6 ± 1.7
taps, p < 0.001) [28]. This was the case despite a significantly
longer time fromTD toVPS (VAD48.8 ± 26.4 days vs. VSGS
80.8 ± 67.5 days, p = 0.012). Furthermore, Lam and Heilman
reported that 16/16 patients with VADs required daily CSF
tapping, compared to only 4/16 patients with VSGSs
(p = 0.000016) [8]. Meta-analysis showed a significantly low-
er proportion of patients with a VSGS requiring CSF tapping
compared to patients with a VAD (Fig. 1a, log OR −4.43,
95 % CI −6.14 to −2.72). However, this did not translate to
significantly higher rates of infection or obstruction with
VADs compared to VSGSs in either study. Infection rates
reported in four studies ranged from 0 to 12.5 % for VADs
and 6.3 to 13.9 % for VSGSs [8, 27–29]. Meta-analysis
showed no significant difference between VAD and VSGS
rates of infection and obstruction (Fig. 1b, c; infection log
OR 0.03, 95 % CI −0.77 to 0.84; obstruction log OR 1.25,
95 % CI −0.21 to 2.71). One study investigated the need for
revision, finding no significant difference between revision
rates in patients with a VAD andVSGS (VAD 3.1% vs. VSGS
10 %, p = 0.16) [27].
Ventriculoperitoneal shunt dependence
The proportion of patients with a VAD and VSGS converted
to VPS varied greatly between studies (58.5–93.8% for VADs
and 60–86 % for VSGSs). Whilst the Wellons et al. study
found borderline significance in the number of patients with
a VSGS requiring a VPS (69.3 % for VADs vs. 86.1 % for
VSGSs, p = 0.05) [29], meta-analysis of the studies found no
significant difference (Fig. 1d, log OR −0.06, 95 % CI −0.93
to 0.82). Subsequent VPS infection rates were comparable
between patients with VADs (4.6–12 %) and VSGSs (3.3–
16 %), with no significant difference following meta-
analysis (Fig. 1e, log OR 0.23, 95 % −0.61 to 1.06).
Mortality
Despite representing a core outcome in the management of
posthaemorrhagic hydrocephalus and the preterm infant, only
three studies reported mortality. In the studies, all mortalities
were unrelated to the posthaemorrhagic hydrocephalus or com-
plications relating to its management [8, 27, 28]. No significant
difference in mortality was found between patients with VADs
and VSGSs in the reporting studies and in meta-analysis of the
data (Fig. 1f, log OR 0.37, 95 % CI −0.95 to 1.70).
Long-term neurodevelopment
Only one study reported neurodevelopmental outcome.
Srinivasakumar et al. utilised the Bayley Scales of Infant
and Toddler development, with results at 18 and 24 months
for 36 % of surviving infants. Comparative testing between
patients with a VAD and VSGS was not significant
(p = 0.9) [26].
Childs Nerv Syst (2016) 32:259–267 261
T
ab
le
2
L
ite
ra
tu
re
se
ar
ch
re
su
lts
C
ita
tio
n
Ty
pe
of
st
ud
y
E
vi
de
nc
e
cl
as
s
S
am
pl
e/
n
D
ef
in
ed
ou
tc
om
e(
s)
R
es
ul
ts
S
T
R
O
B
E
sc
or
e
(/
34
)*
C
om
m
en
ts
W
an
g
et
al
.[
26
]
R
et
ro
sp
ec
tiv
e
co
ho
rt
4
V
A
D
=
44
1.
N
um
be
r
of
T
D
C
SF
ta
ps
V
A
D
in
se
rt
io
n
w
as
pr
ed
ic
tiv
e
of
m
or
e
C
SF
ta
ps
pr
io
r
to
V
PS
pl
ac
em
en
tc
om
pa
re
d
w
ith
V
SG
S
pl
ac
em
en
t
(1
0
±
8.
7
ta
ps
vs
1.
6
±
1.
7
ta
ps
,p
<
0.
00
1)
.N
o
si
gn
if
ic
an
td
if
fe
re
nc
es
in
th
e
ra
te
s
of
T
D
in
fe
ct
io
n
re
qu
ir
in
g
re
m
ov
al
(V
A
D
6.
8
%
,V
SG
S
6.
5
%
,
p
=
0.
96
),
V
P
S
in
se
rt
io
n
(V
A
D
77
.3
%
,V
SG
S
76
.1
%
,
p
=
0.
89
)
or
ea
rl
y
V
PS
in
fe
ct
io
n
(V
A
D
11
.4
%
,V
S
G
S
13
.0
%
,p
=
0.
78
)
28
V
A
D
da
ta
co
lle
ct
ed
19
98
–2
00
7,
V
S
G
S
da
ta
co
lle
ct
ed
20
08
–2
01
1
fo
llo
w
in
g
sw
itc
h
du
e
to
th
eo
ri
se
d
be
ne
fi
t.
Po
ss
ib
ili
ty
of
se
le
ct
io
n
bi
as
.I
nc
om
pl
et
e
V
A
D
fo
llo
w
-u
p
da
ta
an
d
im
ag
in
g.
N
o
lo
ng
-t
er
m
ne
ur
od
ev
el
op
m
en
ta
l
ou
tc
om
es
.S
ig
ni
fi
ca
nt
di
ff
er
en
ce
s
in
ge
st
at
io
na
la
ge
an
d
m
ea
n
w
ei
gh
tb
et
w
ee
n
th
e
tw
o
gr
ou
ps
V
S
G
S
=
46
To
ta
l
=
90
2.
T
D
in
fe
ct
io
n
3.
V
PS
co
nv
er
si
on
4.
V
PS
in
fe
ct
io
n
L
am
an
d
H
ei
lm
an
[6
]
R
et
ro
sp
ec
tiv
e
co
ho
rt
3b
V
A
D
=
16
1.
N
ee
d
fo
r
C
SF
ta
ps
16
/1
6
pa
tie
nt
s
w
ith
V
A
D
re
qu
ir
ed
da
ily
ta
ps
w
hi
le
4/
16
pa
tie
nt
s
w
ith
V
SG
S
re
qu
ir
ed
da
ily
ta
ps
(p
=
0.
00
00
16
).
1
ob
st
ru
ct
io
n
w
as
fo
un
d
in
th
e
V
A
D
gr
ou
p
co
m
pa
re
d
to
3
ob
st
ru
ct
io
ns
in
th
e
V
SG
S
gr
ou
p
(p
=
0.
17
).
1
C
SF
in
fe
ct
io
n
w
as
fo
un
d
in
th
e
V
SG
S
gr
ou
p.
15
/1
6
(9
3.
8
%
)
of
pa
tie
nt
s
w
ith
V
A
D
re
qu
ir
ed
a
pe
rm
an
en
tV
PS
co
m
pa
re
d
to
10
/1
4
(7
1.
4
%
)
pa
tie
nt
s
w
ith
V
S
G
S.
Tw
o
pa
tie
nt
s
w
ith
V
SG
S
di
ed
fr
om
co
m
pl
ic
at
io
ns
un
re
la
te
d
to
th
e
T
D
su
rg
er
y
22
N
o
si
gn
if
ic
an
td
if
fe
re
nc
e
be
tw
ee
n
th
e
m
ea
n
ge
st
at
io
na
la
ge
an
d
m
ea
n
bi
rt
h
w
ei
gh
to
f
th
e
V
A
D
an
d
V
SG
SS
gr
ou
ps
.
N
o
lo
ng
-t
er
m
ne
ur
od
ev
el
op
m
en
ta
lo
ut
co
m
es
V
S
G
S
=
16
2.
T
D
in
fe
ct
io
n
To
ta
l
=
32
3.
T
D
ob
st
ru
ct
io
n
4.
V
PS
co
nv
er
si
on
S
ri
ni
va
sa
ku
m
ar
et
al
.[
24
]
R
et
ro
sp
ec
tiv
e
co
ho
rt
3b
V
A
D
=
29
1.
E
ar
ly
vs
.l
at
e
in
te
rv
en
tio
n
17
/2
9
(5
8.
5
%
)
w
ith
V
A
D
ve
rs
us
15
/2
5
(6
0.
0
%
)
w
ith
V
SG
S
un
de
rw
en
tV
PS
pl
ac
em
en
t(
p
=
0.
7)
.
In
te
rv
en
tio
ns
w
er
e
co
m
pa
ra
bl
e
w
ith
re
sp
ec
tt
o
m
or
ta
lit
y
ra
te
(p
=
0.
8)
,i
nf
ec
tio
n
ra
te
(p
=
0.
3)
,r
ev
is
io
n
ra
te
(p
=
0.
9)
,f
ol
lo
w
-u
p
(p
=
0.
9)
,a
nd
ne
ur
od
ev
el
op
m
en
ta
l
ou
tc
om
e
(p
=
0.
9)
at
18
to
24
m
on
th
s
31
L
im
ite
d
fo
llo
w
-u
p
in
fo
rm
at
io
n
av
ai
la
bl
e.
L
ac
k
of
ne
ur
oi
m
ag
in
g
to
de
te
rm
in
e
th
e
im
pa
ct
of
w
hi
te
m
at
te
r
in
ju
ry
.N
ot
po
ss
ib
le
to
as
ce
rt
ai
n
ov
er
la
p
w
ith
si
m
ila
r
st
ud
y
fr
om
sa
m
e
ce
nt
re
V
S
G
S
=
25
To
ta
l
=
54
2.
V
PS
co
nv
er
si
on
3.
N
eu
ro
de
ve
lo
pm
en
ta
l
ou
tc
om
e
L
im
br
ic
k
et
al
.
[2
5]
R
et
ro
sp
ec
tiv
e
co
ho
rt
3b
V
A
D
=
65
1.
T
D
in
fe
ct
io
n
49
(7
5.
4
%
)
pa
tie
nt
s
w
ith
V
A
D
an
d
20
(6
6.
7
%
)
pa
tie
nt
s
w
ith
V
SG
S
re
qu
ir
ed
V
PS
s
(p
=
0.
38
).
N
o
st
at
is
tic
al
di
ff
er
en
ce
be
tw
ee
n
V
A
D
or
V
SG
S
w
ith
re
ga
rd
to
de
vi
ce
in
fe
ct
io
n
(V
A
D
6.
2
%
,V
SG
S
3.
3
%
,p
=
0.
57
),
ne
ed
fo
r
re
vi
si
on
(V
A
D
3.
1
%
,V
SG
S
10
%
,p
=
0.
16
),
su
bs
eq
ue
nt
V
PS
in
fe
ct
io
n
(V
A
D
4.
6
%
,V
SG
S
3.
3
%
,
p
=
0.
77
),
V
PS
re
vi
si
on
ra
te
(p
=
0.
58
)
or
m
or
ta
lit
y
ra
te
(V
A
D
6.
2
%
,V
SG
S
13
.3
%
,p
=
0.
24
)
29
Si
ng
le
in
st
itu
tio
n
st
ud
y
of
on
ly
si
x
su
rg
eo
ns
.L
ac
k
of
cr
ite
ri
a
fo
r
tim
in
g
of
T
D
,c
re
at
in
g
in
he
re
nt
va
ri
ab
ili
ty
an
d
co
nf
ou
nd
er
s.
N
o
lo
ng
-t
er
m
ne
ur
od
ev
el
op
m
en
ta
l
ou
tc
om
es
V
S
G
S
=
30
2.
T
D
ob
st
ru
ct
io
n
To
ta
l
=
95
3.
V
PS
co
nv
er
si
on
4.
V
PS
in
fe
ct
io
n
5.
V
PS
re
vi
si
on
6.
M
or
ta
lit
y
ra
te
W
el
lo
ns
et
al
.
[2
7]
R
et
ro
sp
ec
tiv
e
co
ho
rt
4
V
A
D
=
88
1.
V
PS
co
nv
er
si
on
61
/8
8
(6
9.
3
%
)
pa
tie
nt
s
w
ho
re
ce
iv
ed
V
A
D
an
d
31
/3
6
(8
6.
1
%
)
pa
tie
nt
s
w
ho
re
ce
iv
ed
V
SG
S
al
so
re
ce
iv
ed
pe
rm
an
en
tC
S
F
di
ve
rs
io
n
w
ith
a
V
PS
(p
=
0.
05
).
11
pa
tie
nt
s
w
ith
V
A
D
(1
3
%
)
ha
d
C
S
F
in
fe
ct
io
ns
,
co
m
pa
re
d
w
ith
5
pa
tie
nt
s
(1
4
%
)
in
th
e
V
SG
S
gr
ou
p
(p
=
0.
83
).
6-
m
on
th
in
ci
de
nc
e
of
pe
rm
an
en
ts
hu
nt
in
fe
ct
io
n
in
pa
tie
nt
s
w
ith
V
A
D
w
as
7/
61
(1
2
%
),
co
m
pa
re
d
w
ith
5/
31
(1
6
%
)
of
pa
tie
nt
s
w
ith
V
SG
S
(p
=
0.
65
)
30
Fo
ur
ce
nt
re
s
in
vo
lv
ed
ea
ch
w
ith
di
ff
er
en
tc
ri
te
ri
a
fo
r
in
iti
al
tr
ea
tm
en
t.
C
ri
te
ri
a
fo
r
us
e
of
T
D
no
ts
ta
nd
ar
di
se
d
an
d
on
ly
tw
o
ce
nt
re
s
pe
rf
or
m
ed
it.
V
ar
ia
tio
ns
be
tw
ee
n
su
rg
eo
ns
in
ea
ch
ce
nt
re
w
er
e
al
so
pr
es
en
t.
N
o
lo
ng
-t
er
m
ne
ur
od
ev
el
op
m
en
ta
lo
ut
co
m
es
V
S
G
S
=
36
2.
T
D
in
fe
ct
io
n
To
ta
l
=
12
4
3.
V
PS
co
nv
er
si
on
4.
V
PS
in
fe
ct
io
n
ra
te
at
6
m
on
th
s
T
D
te
m
po
ri
si
ng
de
vi
ce
,V
P
S
ve
nt
ri
cu
lo
pe
ri
to
ne
al
sh
un
t
*S
T
R
O
B
E
sc
or
e
ou
to
f
33
fo
r
st
ud
ie
s
w
ith
no
m
is
si
ng
da
ta
262 Childs Nerv Syst (2016) 32:259–267
Criteria
Various criteria were reviewed relating to the decision to place
a TD, the TD type, at which point(s) CSF tapping was indi-
cated, when VPS conversion was indicated and patient inclu-
sion in the studies (Table 3). TD placement criteria varied
between studies, but common indications included clinical
instability of the infant, identified PHVD or external signs of
raised intracranial pressure. Two studies gave no detail relat-
ing to indications for TD placement. The decision on the type
of TD was either due to surgeon training or preference, or the
preference of the centre. Two studies evaluated centres that
had transitioned all treatment from VAD to VSGS on the
grounds of theorised benefits of the VSGS [8, 28].
Indications for CSF tapping included instability of vital
signs, rapid increase in head circumference, signs of hydro-
cephalus on cranial ultrasonography and failure of adequate
absorption of the subgaleal pocket in patients with VSGSs.
Whilst one study reported routine tapping until signs of hy-
drocephalus resolved [8], two studies indicated CSF tapping
as required [27, 28]. The two remaining studies provided no
clear details of CSF tapping protocols [26, 29]. For treatment
of CSF infection, one study reported removing the device
based on surgeon preference [28]. Specific VPS conversion
criteria varied greatly between studies but included elements
related to the weight and estimated gestational age (EGA) of
the infant, vital sign deterioration, persisting PHVD and need
for CSF tapping. Furthermore, criteria for patient inclusion in
the study varied. Three studies specified patients with a diag-
nosed grade III or IV IVH [26, 27, 29]. Two studies specified a
weight of less than 1500 g [27, 29]. Exclusion criteria includ-
ed patients with congenital central nervous system
malformations and stroke, and those who received care out-
side of the facility studied [26, 29]. Where specified, EGA for
the patients included ranged from 34 to 40 weeks [26–28].
Discussion
Identifying the optimal temporising device for PHH is impor-
tant in limiting potentially devastating consequences from this
complication of IVH. The decision to use either a VAD or
VSGS remains poorly understood [11], and this is the first
review to compare these temporising devices in a systematic
way across multiple outcomes and meta-analyse the results
where possible. Whilst criteria for diagnosing IVH were
somewhat comparable in the characteristics reviewed, specific
measures or thresholds for subsequent PPHVD were not re-
ported in any included study. This finding corroborates a sur-
vey of neonatologists that demonstrated substantial heteroge-
neity of diagnosis and management of this condition across
Europe [30].
For those studies that reported TD infection rates, two of
the five studies included criteria for infection (CSF culture
positivity) [27, 28]. Although CSF tapping has been associat-
ed with an increased risk of infection [10], the results here
demonstrate that, despite a significantly higher rate of tapping
in patients with a VAD, there is no evidence to suggest a
higher rate of infection of the VAD relative to the VSGS.
Despite the theoretical risks, it is hypothesised that the use
of rigorous protocols for CSF tapping minimises the infection
rate for VADs [31]. Methods of CSF tapping used to minimise
infection were not described, but the range of infection rates
reported suggests potential differences between centres in ab-
solute infection rates.
The significantly reduced rate of tapping may be an attrac-
tive feature of VSGS for neurosurgical units in certain local-
ities.Whilst in North America these infants are likely to stay at
the neurosurgical centre for the majority of their neonatal care,
where tapping of the VAD can be supervised and performed
by neurosurgical professionals, many European centres will
discharge these children soon after surgery to their local neo-
natal unit for ongoing care. The lack of Bcontrol^ over fre-
quency and technique of tapping in peripheral hospitals may
push these units towards the use of VSGS. Standard protocols
for indications for CSF tapping were not consistently used
across studies, including the clinical indications, timing of
tapping and volume of CSF extracted. Furthermore, standard
protocols for the treatment of CSF infection or TD obstruction
were not described in the studies included in this review.
VPS conversion and subsequent infection was not signifi-
cantly different between patients managed with a VAD or
VSGS, but this finding is confounded by the heterogeneity
in timing and criteria used to decide when to convert to a
permanent VPS; the time interval from TD to VPS was
analysed in only one study [28]. Similar to the TD infection
rate, the VPS infection rate varied greatly between studies.
Protocols for management of VPS infections were not de-
scribed in the studies included in this review.
With regard to mortality and neurodevelopmental status,
there is potential selection bias as Wellons et al. excluded pa-
tients who died and Limbrick et al. reported substantial co-
morbidities that contributed to the mortality rate [27, 29]. Fur-
thermore, all of the aforementioned outcome measures are po-
tential confounders, in particular TD and VPS infection. The
length of follow-up in studies also varied greatly, with no stan-
dard criteria for the determination of a mortality rate reported. A
multivariable model approach would better elucidate the factors
contributing to long-term neurodevelopmental outcome.
The results affirm the importance of an ongoing
multicentre, prospective pilot study comparing these
two temporising procedures to enable a more robust
comparison, with standardisation of protocols across di-
agnosis, TD insertion, VPS conversion and measurement
of long-term outcome [32].
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Limitations
The absences of a rationale for the sample size, a participant
flow diagram or the use of sensitivity analysis were key omis-
sions that reduced the STROBE scores for the included stud-
ies. Major specific limitations identified in the studies include
he t e rogene i ty o f pa t i en t coho r t s [28 ] , l a ck o f
neurodevelopmental follow-up [8, 27–29], absence of
standardised criteria for the management of this condition
and variations between surgeons creating inherent variability
and confounders [27, 29]. Limited sample sizes reduced sta-
tistical power in all studies. The meta-analysis presented gives
estimates across core outcomes to provide results from a larger
sample. However, whilst heterogeneity was assessed statisti-
cally in the meta-analysis, it was nonetheless performed on a
series of retrospective studies with substantial heterogeneity in
the criteria for management and reporting of outcomes in pa-
tients with posthaemorrhagic hydrocephalus.
Conclusion
This study reports, in an objective and systematic fashion, the
current state of the literature regarding which TD (VAD or
Fig. 1 Meta-analysis of VSGS
relative to VAD. Statistics
presented are Cochran’s Q with p
value test for heterogeneity and
log odds ratio (OR) with 95 %
confidence intervals (CI). An
asterisk represents the results for
VPS conversion rate from
Srinivasakumar et al. [26]
excluded due to potential overlap
with Limbrick et al. [27]
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VSGS) is superior for the management of PHH in preterm
infants. The systematic search revealed an absence of
randomised controlled trials investigating this clinical equi-
poise. Five studies of poor quality (three class 3b studies and
two class 4 studies) were identified and reviewed, with an
observational study meta-analysis performed. There is evi-
dence to suggest fewer CSF tappings are necessary with a
ventriculosubgaleal shunt. Meta-analysis showed no signifi-
cant differences between VAD and VSGS in rates of
temporising device infection, obstruction, the requirements
for a ventriculoperitoneal shunt, infection of the subsequent
shunt and overall mortality. Heterogeneity of included studies
reaffirms the importance of standardised criteria for initial
management and reporting outcomes, along with a more sys-
tematic approach to sustained follow-up to enable a better
understanding of long-term neurodevelopment of these pa-
tients. There is not current sufficient data to suggest superior-
ity of one TD over the other, although the reduced rate of CSF
tapping in VSGS may make this option attractive in certain
healthcare systems.
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